NATCO Pharma shares tumbled 10% on Friday, extending a two-day slump to 28% after weak Q3 results and a target price cut by Nuvama. Profit fell 37.75% YoY, impacted by lower formulations exports and Agrochem weakness. Despite a strong U.S. pipeline and cash reserves, analysts remain cautious on near-term growth.
Wait for dust to settle before taking fresh bets, says Maulik Patel
Geopolitical tensions and market swings prompt caution for investors. Maulik Patel of Equirus Securities advises patience, suggesting a wait-and-watch approach. He notes current crises differ